A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Crenigacestat (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Eli Lilly
- 25 Oct 2017 Outcomes of population PK/PD model developed using data from first human dose trial (NCT01695005,n=102) and single ascending dose and pilot relative bioavailability study (NCT02659865,n=34),presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.
- 15 Sep 2017 Planned End Date changed from 1 May 2020 to 1 Jun 2018.
- 15 Sep 2017 Planned primary completion date changed from 1 May 2019 to 1 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History